The FDA and FTC continue their crack down on COVID-19 related product claims. According to an article from The National Law Review, these two regulatory bodies have now jointly issued warning letters regarding such claims to multiple CBD companies.
Adding to this increased regulation are measures being taken by the U.S. Food & Drug Administration (FDA). Like other regulators, such as the Federal Trade Commission (FTC), the FDA is making a point of upping its game. While the FDA has always been an ardent protector of public health through its enforcement policies, they are adapting to new sales techniques by increasing their scrutiny of social media promotion.
The FDA and the FTC posted warning letters to 10 companies for illegally selling dietary supplements that claim to cure, treat, mitigate, or prevent diabetes, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
In the wake of recent FTC actions, a new pattern of consumer protection action has emerged: companies who go too far in their marketing or give the appearance of an anti-consumer bias may be putting their companies at great risk.